Pharmacological inhibition of NHE1 protein attenuated pathological Aβ plaque density, and hyperactive locomotor behaviors in APP mice, highlighting NHE1 as a possible therapeutic target for AD. This evidence concerns the gene SLC9A1 and Alzheimer disease.